CARMEL, Ind., March 19, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will report financial results for its fourth quarter and fiscal year 2023 ended December 31, 2023, on Monday, March 25, 2024, before the market opens. The Company has scheduled a conference call for that same day, March 25, 2024, at 9:00 a.m. ET, to review the results.
Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.
Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast replay will be available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.94 |
Daily Change: | -0.06 -5.86 |
Daily Volume: | 138,116 |
Market Cap: | US$6.220M |
August 08, 2024 July 30, 2024 May 14, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB